To continue reading this article, sign up for FREE to
Membership is FREE
and provides you with
instant access
to email newsletters, digital publications, our full content catalogue & more...
Oncolytics Biotech Completes Initial Scale Up of Manufacturing Process for REOLYSIN® to Commercial Scale
Oncolytics Biotech Inc. has announced that it has successfully completed initial scale up of its manufacturing process for REOLYSIN® to commercial scale.
The scale up of primary production and downstream processing development was undertaken by the National Research Council Biotechnology Research Institute (NRC-BRI) located in Montreal, Canada.
"Our existing manufacturing capacity at 40 litres allows us to support future pivotal clinical studies with REOLYSIN®," said Dr. Matt Coffey, Chief Scientific Officer of Oncolytics. "Using this process, a 100-litre manufacturing facility has the potential to produce more than one million doses a year for intravenous use."
Add Technology Networks as a preferred Google source to see more of our trusted coverage.
